Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Evidence-based clinical practice guideline aims to optimize PD-L1 lung tumor testing

The College of American Pathologists (CAP), in collaboration with five other societies, developed a draft evidence-based clinical practice guideline that aims to optimize PD-L1 testing for patients with non-small cell lung cancer (NSCLC) who are being considered for immunooncology therapy.

1 Apr 2021

NCCN Annual Conference discusses new ways to improve cancer care

New recommendations to advance racial equity, ways to mitigate the impacts of the COVID-19 pandemic on cancer care, and ongoing strategies for preventing and controlling HPV-associated cancers led the conversation at the National Comprehensive Cancer Network® (NCCN®) 2021 Virtual Annual Conference March 18-20.

25 Mar 2021

Novel method can improve the detection of circulating tumor cells

Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases.

10 Mar 2021

Newly identified biomarker could predict response to immune checkpoint inhibitors

A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.

3 Mar 2021

COVID-19 and lung cancer have a common pathway, say researchers

A new preprint on the bioRxiv* server describes the common features COVID-19 shares with lung cancer.

19 Feb 2021

Combination therapy produces clinical benefit for early stage non-small cell lung cancer

The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.

18 Feb 2021

FDA approves drug to reduce frequency of chemotherapy-induced bone marrow suppression

Today, the U.S. Food and Drug Administration approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving certain types of chemotherapy for extensive-stage (when the cancer has spread beyond the lungs) small cell lung cancer.

13 Feb 2021

Researchers use cachexia model to assess cancer-derived myocardial impairments

Oncotarget recently published "Evaluation of cancer-derived myocardial impairments using a mouse model" which reported that Myocardial damage in cancer patients is emphasized as a cause of death; however, there are not many murine cachexia models to evaluate cancer-derived heart disorder.

11 Feb 2021

AI technology can help prevent adverse effect of immunotherapy in certain lung cancer patients

Researchers at Case Western Reserve University, using artificial intelligence (AI) to analyze simple tissue scans, say they have discovered biomarkers that could tell doctors which lung cancer patients might actually get worse from immunotherapy.

5 Feb 2021

Biomarkers could help discriminate cancer therapy-associated kidney injury from other causes

A study by Mayo Clinic researchers published in Kidney International Reports finds that immune checkpoint inhibitors, may have negative consequences in some patients, including acute kidney inflammation, known as interstitial nephritis. Immune checkpoint inhibitors are used to treat cancer by stimulating the immune system to attack cancerous cells.

3 Feb 2021

Phase III study of (m)RNA expression did not confer significant advantage for stage II-III lung cancer

A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.

31 Jan 2021

LCMC3 trial: Neoadjuvant atezolizumab prior to lung cancer surgery meets primary endpoint

(Primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study revealed that neoadjuvant atezolizumab prior to lung cancer surgery was well tolerated by patients and met its primary endpoint of 20% major pathologic response rate, according to research presented today at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer.

31 Jan 2021

Residential segregation, discriminatory practices impact outcomes of Black lung cancer patients

Structural racism thwarts a large proportion of black patients from receiving appropriate lung cancer care, resulting in worse outcomes and shorter lifespans than white patients with the disease, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.

29 Jan 2021

New approach to capture natural killer cells and harvest cancer-killing packets

Building on the promise of emerging therapies to deploy the body's "natural killer" immune cells to fight cancer, researchers at the University of Michigan Rogel Cancer Center and U-M College of Engineering have gone one step further.

28 Jan 2021

Genetic changes in tumors can help predict the efficacy of immunotherapy drugs

Researchers at the Francis Crick Institute, the UCL Cancer Institute, and the Cancer Research UK Lung Cancer Centre of Excellence have identified genetic changes in tumors which could be used to predict if immunotherapy drugs would be effective in individual patients.

28 Jan 2021

Missing surface protein allows small cell lung cancer cells to hide from immune defenses

Small cell lung cancer (SCLC) cells are missing a surface protein that triggers an immune response, allowing them to hide from one of the body's key cancer defenses, a new study led by UT Southwestern researchers suggests.

25 Jan 2021

Researchers develop comprehensive framework to classify small-cell lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study published today in Cancer Cell.

22 Jan 2021

Researchers discover new metabolic vulnerability in a highly aggressive form of lung cancer

Researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC).

5 Jan 2021

Study uncovers why cancer patients with liver metastases have poor outcomes

Michael Green, M.D., Ph.D., noticed that when his patients had cancer that spread to the liver, they fared poorly – more so than when cancer spread to other parts of the body. Not only that, but transformative immunotherapy treatments had little impact for these patients.

4 Jan 2021

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.

18 Dec 2020